BridgeBio Oncology Therapeutics Inc. (BBOT) Options Greeks

Options Greeks measure sensitivity to various factors: Delta (price), Gamma (delta change), Theta (time decay), and Vega (volatility). They are essential for risk management and position sizing.

BridgeBio Oncology Therapeutics Inc. (BBOT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $718.6M, listed on NASDAQ, employing roughly 62 people, carrying a beta of 0.22 to the broader market. BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Led by Eli Wallace, public since 2025-08-12.

Options Greeks analysis provides sensitivity measures for price, time, and volatility. No recent options activity for BBOT as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how options Greeks is reported and how to read the data →